Full Text of HB2534 100th General Assembly
HB2534enr 100TH GENERAL ASSEMBLY |
| | HB2534 Enrolled | | LRB100 08419 RLC 18533 b |
|
| 1 | | AN ACT concerning criminal law.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Sections 204, 206, 208, 401, and 402 as | 6 | | follows: | 7 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | 8 | | Sec. 204. (a) The controlled substances listed in this | 9 | | Section are
included in Schedule I. | 10 | | (b) Unless specifically excepted or unless listed in | 11 | | another
schedule, any of the following opiates, including their | 12 | | isomers,
esters, ethers, salts, and salts of isomers, esters, | 13 | | and ethers,
whenever the existence of such isomers, esters, | 14 | | ethers and salts is
possible within the specific chemical | 15 | | designation: | 16 | | (1) Acetylmethadol; | 17 | | (1.1) Acetyl-alpha-methylfentanyl | 18 | | (N-[1-(1-methyl-2-phenethyl)-
| 19 | | 4-piperidinyl]-N-phenylacetamide); | 20 | | (2) Allylprodine; | 21 | | (3) Alphacetylmethadol, except
| 22 | | levo-alphacetylmethadol (also known as levo-alpha-
| 23 | | acetylmethadol, levomethadyl acetate, or LAAM); |
| | | HB2534 Enrolled | - 2 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (4) Alphameprodine; | 2 | | (5) Alphamethadol; | 3 | | (6) Alpha-methylfentanyl
| 4 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| 5 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| 6 | | propanilido) piperidine; | 7 | | (6.1) Alpha-methylthiofentanyl
| 8 | | (N-[1-methyl-2-(2-thienyl)ethyl-
| 9 | | 4-piperidinyl]-N-phenylpropanamide); | 10 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | 11 | | (7.1) PEPAP
| 12 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | 13 | | (8) Benzethidine; | 14 | | (9) Betacetylmethadol; | 15 | | (9.1) Beta-hydroxyfentanyl
| 16 | | (N-[1-(2-hydroxy-2-phenethyl)-
| 17 | | 4-piperidinyl]-N-phenylpropanamide); | 18 | | (10) Betameprodine; | 19 | | (11) Betamethadol; | 20 | | (12) Betaprodine; | 21 | | (13) Clonitazene; | 22 | | (14) Dextromoramide; | 23 | | (15) Diampromide; | 24 | | (16) Diethylthiambutene; | 25 | | (17) Difenoxin; | 26 | | (18) Dimenoxadol; |
| | | HB2534 Enrolled | - 3 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (19) Dimepheptanol; | 2 | | (20) Dimethylthiambutene; | 3 | | (21) Dioxaphetylbutyrate; | 4 | | (22) Dipipanone; | 5 | | (23) Ethylmethylthiambutene; | 6 | | (24) Etonitazene; | 7 | | (25) Etoxeridine; | 8 | | (26) Furethidine; | 9 | | (27) Hydroxpethidine; | 10 | | (28) Ketobemidone; | 11 | | (29) Levomoramide; | 12 | | (30) Levophenacylmorphan; | 13 | | (31) 3-Methylfentanyl
| 14 | | (N-[3-methyl-1-(2-phenylethyl)-
| 15 | | 4-piperidyl]-N-phenylpropanamide); | 16 | | (31.1) 3-Methylthiofentanyl
| 17 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
| 18 | | 4-piperidinyl]-N-phenylpropanamide); | 19 | | (32) Morpheridine; | 20 | | (33) Noracymethadol; | 21 | | (34) Norlevorphanol; | 22 | | (35) Normethadone; | 23 | | (36) Norpipanone; | 24 | | (36.1) Para-fluorofentanyl
| 25 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 26 | | 4-piperidinyl]propanamide); |
| | | HB2534 Enrolled | - 4 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (37) Phenadoxone; | 2 | | (38) Phenampromide; | 3 | | (39) Phenomorphan; | 4 | | (40) Phenoperidine; | 5 | | (41) Piritramide; | 6 | | (42) Proheptazine; | 7 | | (43) Properidine; | 8 | | (44) Propiram; | 9 | | (45) Racemoramide; | 10 | | (45.1) Thiofentanyl
| 11 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
| 12 | | 4-piperidinyl]-propanamide); | 13 | | (46) Tilidine; | 14 | | (47) Trimeperidine; | 15 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
| 16 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 17 | | N-phenylpropanamide) ; . | 18 | | (49) Furanyl fentanyl (FU-F); | 19 | | (50) Butyryl fentanyl; | 20 | | (51) Valeryl fentanyl; | 21 | | (52) Acetyl fentanyl; | 22 | | (53) Beta-hydroxy-thiofentanyl; | 23 | | (54) 3,4-dichloro-N-[2-
| 24 | | (dimethylamino)cyclohexyl]-N-
| 25 | | methylbenzamide (U-47700); | 26 | | (55) 4-chloro-N-[1-[2-
|
| | | HB2534 Enrolled | - 5 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (4-nitrophenyl)ethyl]-2-piperidinylidene]-
| 2 | | benzenesulfonamide (W-18); | 3 | | (56) 4-chloro-N-[1-(2-phenylethyl)
| 4 | | -2-piperidinylidene]-benzenesulfonamide (W-15); | 5 | | (57) acrylfentanyl (acryloylfentanyl). | 6 | | (c) Unless specifically excepted or unless listed in | 7 | | another
schedule, any of the following opium derivatives, its | 8 | | salts, isomers
and salts of isomers, whenever the existence of | 9 | | such salts, isomers and
salts of isomers is possible within the | 10 | | specific chemical designation: | 11 | | (1) Acetorphine; | 12 | | (2) Acetyldihydrocodeine; | 13 | | (3) Benzylmorphine; | 14 | | (4) Codeine methylbromide; | 15 | | (5) Codeine-N-Oxide; | 16 | | (6) Cyprenorphine; | 17 | | (7) Desomorphine; | 18 | | (8) Diacetyldihydromorphine (Dihydroheroin); | 19 | | (9) Dihydromorphine; | 20 | | (10) Drotebanol; | 21 | | (11) Etorphine (except hydrochloride salt); | 22 | | (12) Heroin; | 23 | | (13) Hydromorphinol; | 24 | | (14) Methyldesorphine; | 25 | | (15) Methyldihydromorphine; | 26 | | (16) Morphine methylbromide; |
| | | HB2534 Enrolled | - 6 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (17) Morphine methylsulfonate; | 2 | | (18) Morphine-N-Oxide; | 3 | | (19) Myrophine; | 4 | | (20) Nicocodeine; | 5 | | (21) Nicomorphine; | 6 | | (22) Normorphine; | 7 | | (23) Pholcodine; | 8 | | (24) Thebacon. | 9 | | (d) Unless specifically excepted or unless listed in | 10 | | another
schedule, any material, compound, mixture, or | 11 | | preparation which contains
any quantity of the following | 12 | | hallucinogenic substances, or which
contains any of its salts, | 13 | | isomers and salts of isomers, whenever the
existence of such | 14 | | salts, isomers, and salts of isomers is possible
within the | 15 | | specific chemical designation (for the purposes of this
| 16 | | paragraph only, the term "isomer" includes the optical, | 17 | | position and
geometric isomers): | 18 | | (1) 3,4-methylenedioxyamphetamine
| 19 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| 20 | | methylenedioxyamphetamine, MDA); | 21 | | (1.1) Alpha-ethyltryptamine
| 22 | | (some trade or other names: etryptamine;
| 23 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 24 | | 3-(2-aminobutyl)indole; a-ET; and AET); | 25 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); | 26 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
| | | HB2534 Enrolled | - 7 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (also known as: N-ethyl-alpha-methyl-
| 2 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| 3 | | and MDEA); | 4 | | (2.2) N-Benzylpiperazine (BZP); | 5 | | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | 6 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | 7 | | (4) 3,4,5-trimethoxyamphetamine (TMA); | 8 | | (5) (Blank); | 9 | | (6) Diethyltryptamine (DET); | 10 | | (7) Dimethyltryptamine (DMT); | 11 | | (7.1) 5-Methoxy-diallyltryptamine; | 12 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | 13 | | (9) Ibogaine (some trade and other names:
| 14 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 15 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| 16 | | indole; Tabernanthe iboga); | 17 | | (10) Lysergic acid diethylamide; | 18 | | (10.1) Salvinorin A; | 19 | | (10.5) Salvia divinorum (meaning all parts of the plant | 20 | | presently classified
botanically as Salvia divinorum, | 21 | | whether growing or not, the
seeds thereof, any extract from | 22 | | any part of that plant, and every compound,
manufacture, | 23 | | salts, isomers, and salts of
isomers whenever the existence | 24 | | of such salts, isomers, and salts of
isomers is possible | 25 | | within the specific chemical designation, derivative, | 26 | | mixture, or preparation of that plant, its
seeds or |
| | | HB2534 Enrolled | - 8 - | LRB100 08419 RLC 18533 b |
|
| 1 | | extracts);
| 2 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | 3 | | (12) Peyote (meaning all parts of the plant presently | 4 | | classified
botanically as Lophophora williamsii
Lemaire, | 5 | | whether growing or not, the
seeds thereof, any extract from | 6 | | any part of that plant, and every compound,
manufacture, | 7 | | salts, derivative, mixture, or preparation of that plant, | 8 | | its
seeds or extracts); | 9 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); | 10 | | (14) N-methyl-3-piperidyl benzilate; | 11 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| 12 | | (also known as N-hydroxy-alpha-methyl-
| 13 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | 14 | | (15) Parahexyl; some trade or other names:
| 15 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| 16 | | dibenzo (b,d) pyran; Synhexyl; | 17 | | (16) Psilocybin; | 18 | | (17) Psilocyn; | 19 | | (18) Alpha-methyltryptamine (AMT); | 20 | | (19) 2,5-dimethoxyamphetamine
| 21 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 22 | | (20) 4-bromo-2,5-dimethoxyamphetamine
| 23 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 24 | | 4-bromo-2,5-DMA); | 25 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| 26 | | Some trade or other names: 2-(4-bromo-
|
| | | HB2534 Enrolled | - 9 - | LRB100 08419 RLC 18533 b |
|
| 1 | | 2,5-dimethoxyphenyl)-1-aminoethane;
| 2 | | alpha-desmethyl DOB, 2CB, Nexus; | 3 | | (21) 4-methoxyamphetamine
| 4 | | (4-methoxy-alpha-methylphenethylamine;
| 5 | | paramethoxyamphetamine; PMA); | 6 | | (22) (Blank); | 7 | | (23) Ethylamine analog of phencyclidine.
| 8 | | Some trade or other names:
| 9 | | N-ethyl-1-phenylcyclohexylamine,
| 10 | | (1-phenylcyclohexyl) ethylamine,
| 11 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | 12 | | (24) Pyrrolidine analog of phencyclidine. Some trade | 13 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | 14 | | PHP; | 15 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | 16 | | (26) 2,5-dimethoxy-4-ethylamphetamine
| 17 | | (another name: DOET); | 18 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| 19 | | (another name: TCPy); | 20 | | (28) (Blank); | 21 | | (29) Thiophene analog of phencyclidine (some trade
| 22 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 23 | | 2-thienyl analog of phencyclidine; TPCP; TCP); | 24 | | (29.1) Benzothiophene analog of phencyclidine Some | 25 | | trade or other names: BTCP or benocyclidine; | 26 | | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); |
| | | HB2534 Enrolled | - 10 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (30) Bufotenine (some trade or other names:
| 2 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 3 | | 3-(2-dimethylaminoethyl)-5-indolol;
| 4 | | 5-hydroxy-N,N-dimethyltryptamine;
| 5 | | N,N-dimethylserotonin; mappine); | 6 | | (31) (Blank); 1-Pentyl-3-(1-naphthoyl)indole | 7 | | Some trade or other names: JWH-018; | 8 | | (32) (Blank); 1-Butyl-3-(1-naphthoyl)indole | 9 | | Some trade or other names: JWH-073; | 10 | | (33) (Blank); 1-[(5-fluoropentyl)-1H-indol-3-yl]- | 11 | | (2-iodophenyl)methanone | 12 | | Some trade or other names: AM-694; | 13 | | (34) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | 14 | | (2-methyloctan-2-yl)phenol | 15 | | Some trade or other names: CP 47,497 | 16 | | and its C6, C8 and C9 homologs; | 17 | | (34.5) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | 18 | | (2-methyloctan-2-yl)phenol), where side chain n=5; | 19 | | and homologues where side chain n=4, 6, or 7; Some | 20 | | trade or other names: CP 47,497; | 21 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | 22 | | (2-methyloctan-2-yl)-6a,7, | 23 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol | 24 | | Some trade or other names: HU-210; | 25 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | 26 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- |
| | | HB2534 Enrolled | - 11 - | LRB100 08419 RLC 18533 b |
|
| 1 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, | 2 | | salts, and salts of isomers; Some trade or other | 3 | | names: HU-210, Dexanabinol; | 4 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 5 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 6 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | 7 | | Some trade or other names: HU-211; | 8 | | (37) (Blank); (2-methyl-1-propyl-1H-indol- | 9 | | 3-yl)-1-naphthalenyl-methanone | 10 | | Some trade or other names: JWH-015; | 11 | | (38) (Blank); 4-methoxynaphthalen-1-yl- | 12 | | (1-pentylindol-3-yl)methanone | 13 | | Some trade or other names: JWH-081; | 14 | | (39) (Blank); 1-Pentyl-3-(4-methyl-1-naphthoyl)indole | 15 | | Some trade or other names: JWH-122; | 16 | | (40) (Blank); 2-(2-methylphenyl)-1-(1-pentyl- | 17 | | 1H-indol-3-yl)-ethanone | 18 | | Some trade or other names: JWH-251; | 19 | | (41) (Blank); 1-(2-cyclohexylethyl)-3- | 20 | | (2-methoxyphenylacetyl)indole | 21 | | Some trade or other names: RCS-8, BTW-8 and SR-18; | 22 | | (42) Any compound structurally derived from | 23 | | 3-(1-naphthoyl)indole or 1H-indol-3-yl- | 24 | | (1-naphthyl)methane by substitution at the | 25 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 26 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
| | | HB2534 Enrolled | - 12 - | LRB100 08419 RLC 18533 b |
|
| 1 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, | 2 | | or 2-(4-morpholinyl)ethyl whether or not further | 3 | | substituted in the indole ring to any extent, whether | 4 | | or not substituted in the naphthyl ring to any extent. | 5 | | Examples of this structural class include, but are | 6 | | not limited to, JWH-018, AM-2201, JWH-175, JWH-184, | 7 | | and JWH-185; | 8 | | (43) Any compound structurally derived from | 9 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | 10 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | 11 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl | 12 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, | 13 | | or 2-(4-morpholinyl)ethyl, whether or not further | 14 | | substituted in the pyrrole ring to any extent, whether | 15 | | or not substituted in the naphthyl ring to any extent. | 16 | | Examples of this structural class include, but are not | 17 | | limited to, JWH-030, JWH-145, JWH-146, JWH-307, and | 18 | | JWH-368; | 19 | | (44) Any compound structurally derived from | 20 | | 1-(1-naphthylmethyl)indene by substitution | 21 | | at the 3-position of the indene ring by alkyl, haloalkyl, | 22 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 23 | | halide, alkyl aryl halide, 1-(N-methyl- | 24 | | 2-piperidinyl)methyl, or 2-(4- | 25 | | morpholinyl)ethyl whether or not further substituted in | 26 | | the indene ring to any extent, whether or not substituted |
| | | HB2534 Enrolled | - 13 - | LRB100 08419 RLC 18533 b |
|
| 1 | | in the naphthyl ring to any extent. Examples of | 2 | | this structural class include, but are not | 3 | | limited to, JWH-176; | 4 | | (45) Any compound structurally derived from | 5 | | 3-phenylacetylindole by substitution at the | 6 | | nitrogen atom of the indole ring with alkyl, haloalkyl, | 7 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 8 | | halide, alkyl aryl halide, 1-(N-methyl-2- | 9 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 10 | | whether or not further substituted in the indole ring | 11 | | to any extent, whether or not substituted in the phenyl | 12 | | ring to any extent. Examples of this structural | 13 | | class include, but are not limited to, JWH-167, | 14 | | JWH-250, JWH-251, and RCS-8; | 15 | | (46) Any compound structurally derived from | 16 | | 2-(3-hydroxycyclohexyl)phenol by substitution | 17 | | at the 5-position of the phenolic ring by alkyl, | 18 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 19 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2- | 20 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 21 | | whether or not substituted in the cyclohexyl ring to any | 22 | | extent. Examples of this structural class | 23 | | include, but are not limited to, CP 47, | 24 | | 497 and its C8 homologue (cannabicyclohexanol); | 25 | | (46.1) Any compound structurally | 26 | | derived from Benzoylindoles: Any compound |
| | | HB2534 Enrolled | - 14 - | LRB100 08419 RLC 18533 b |
|
| 1 | | containing a 3-(benzoyl) indole structure with | 2 | | substitution at the nitrogen atom of the | 3 | | indole ring by an alkyl, haloalkyl, alkenyl, | 4 | | cycloalkylmethyl, cycloalkylethyl, | 5 | | aryl halide, alkyl aryl halide, | 6 | | 1-(N-methyl-2-piperidinyl)methyl, | 7 | | or 2-(4-morpholinyl)ethyl group | 8 | | whether or not further substituted | 9 | | in the indole ring to any extent and | 10 | | whether or not substituted in the phenyl ring | 11 | | to any extent. Examples of this structural class | 12 | | include, but are not limited , to , AM-630, | 13 | | AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; | 14 | | (47) (Blank); 3,4-Methylenedioxymethcathinone | 15 | | Some trade or other names: Methylone; | 16 | | (48) (Blank); 3,4-Methyenedioxypyrovalerone | 17 | | Some trade or other names: MDPV; | 18 | | (49) (Blank); 4-Methylmethcathinone | 19 | | Some trade or other names: Mephedrone; | 20 | | (50) (Blank); 4-methoxymethcathinone; | 21 | | (51) (Blank); 4-Fluoromethcathinone; | 22 | | (52) (Blank); 3-Fluoromethcathinone; | 23 | | (53) 2,5-Dimethoxy-4-(n)-propylthio- | 24 | | phenethylamine ; | 25 | | Some trade or other names: 2C-T-7; | 26 | | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine |
| | | HB2534 Enrolled | - 15 - | LRB100 08419 RLC 18533 b |
|
| 1 | | Some trade or other names: 2C-E; | 2 | | (53.2) 2,5-dimethoxy-4-methylphenethylamine | 3 | | Some trade or other names: 2C-D; | 4 | | (53.3) 4-chloro-2,5-dimethoxyphenethylamine | 5 | | Some trade or other names: 2C-C; | 6 | | (53.4) 4-iodo-2,5-dimethoxyphenethylamine | 7 | | Some trade or other names: 2C-I; | 8 | | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine | 9 | | Some trade or other names: 2C-T-2; | 10 | | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine | 11 | | Some trade or other names: 2C-T-4; | 12 | | (53.7) 2,5-dimethoxyphenethylamine | 13 | | Some trade or other names: 2C-H; | 14 | | (53.8) 2,5-dimethoxy-4-nitrophenethylamine | 15 | | Some trade or other names: 2C-N; | 16 | | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine | 17 | | Some trade or other names: 2C-P; | 18 | | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine | 19 | | Some trade or other names: 2C-G; | 20 | | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | 21 | | phenethylamine referred to in subparagraphs (20.1), (53), | 22 | | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | 23 | | (53.8), (53.9), and (53.10) including, but not limited to, | 24 | | 25I-NBOMe and 25C-NBOMe; | 25 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; | 26 | | (55) (Blank); Pentedrone; |
| | | HB2534 Enrolled | - 16 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (56) (Blank); 4-iodo-2,5-dimethoxy-N-((2-methoxy | 2 | | phenyl)methyl)-benzeneethanamine | 3 | | (trade or other name: 25I-NBOMe); | 4 | | (57) (Blank); 4-chloro-2,5-dimethoxy- | 5 | | N-[(2-methoxyphenyl) methyl]-benzeneethanamine | 6 | | (trade or other name: 25C-NBOMe); | 7 | | (58) (Blank); 4-bromo-2,5-dimethoxy | 8 | | -N-[(2-methoxyphenyl) methyl]-benzeneethanamine | 9 | | (trade or other name: 25B-NBOMe); | 10 | | (59) 3-cyclopropoylindole with | 11 | | substitution at the nitrogen atom of the | 12 | | indole ring by alkyl, haloalkyl, alkenyl, | 13 | | cycloalkylmethyl, cycloalkylethyl, aryl | 14 | | halide, alkyl aryl halide, | 15 | | 1-(N-methyl-2-piperidinyl)methyl, or | 16 | | 2-(4-morpholinyl)ethyl, whether or not | 17 | | further substituted on the indole ring | 18 | | to any extent, whether or not substituted | 19 | | on the cyclopropyl ring to any extent: | 20 | | including , but not limited to , XLR11, | 21 | | UR144, FUB-144; | 22 | | (60) 3-adamantoylindole with | 23 | | substitution at the nitrogen atom of the | 24 | | indole ring by alkyl, haloalkyl, alkenyl, | 25 | | cycloalkylmethyl, cycloalkylethyl, | 26 | | aryl halide, alkyl aryl halide, |
| | | HB2534 Enrolled | - 17 - | LRB100 08419 RLC 18533 b |
|
| 1 | | 1-(N-methyl-2-piperidinyl)methyl, or | 2 | | 2-(4-morpholinyl)ethyl, whether or not | 3 | | further substituted on the indole ring to | 4 | | any extent, whether or not substituted on | 5 | | the adamantyl ring to any extent: including , | 6 | | but not limited to , AB-001; | 7 | | (61) N-(adamantyl)-indole-3-carboxamide | 8 | | with substitution at the nitrogen atom of the | 9 | | indole ring by alkyl, haloalkyl, alkenyl, | 10 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, | 11 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, | 12 | | or 2-(4-morpholinyl)ethyl, whether or not further | 13 | | substituted on the indole ring to any extent, whether | 14 | | or not substituted on the adamantyl ring to any | 15 | | extent: including , but not limited to , | 16 | | APICA/2NE-1, STS-135; | 17 | | (62) N-(adamantyl)-indazole-3-carboxamide | 18 | | with substitution at a nitrogen atom of the indazole | 19 | | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 20 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 21 | | 1-(N-methyl-2-piperidinyl)methyl, or | 22 | | 2-(4-morpholinyl)ethyl, whether or not further | 23 | | substituted on the indazole ring to any extent, | 24 | | whether or not substituted on the adamantyl | 25 | | ring to any extent: including , but not limited | 26 | | to , AKB48, 5F-AKB48; |
| | | HB2534 Enrolled | - 18 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (63) 1H-indole-3-carboxylic acid 8-quinolinyl | 2 | | ester with substitution at the nitrogen atom of the | 3 | | indole ring by alkyl, haloalkyl, alkenyl, | 4 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl | 5 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 6 | | 2-(4-morpholinyl)ethyl, whether or not further | 7 | | substituted on the indole ring to any extent, | 8 | | whether or not substituted on the quinoline ring | 9 | | to any extent: including , but not limited to , PB22, | 10 | | 5F-PB22, FUB-PB-22; | 11 | | (64) 3-(1-naphthoyl)indazole with | 12 | | substitution at the nitrogen atom of the | 13 | | indazole ring by alkyl, haloalkyl, | 14 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, | 15 | | aryl halide, alkyl aryl halide, | 16 | | 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further | 18 | | substituted on the indazole ring to any extent, | 19 | | whether or not substituted on the naphthyl ring | 20 | | to any extent: including , but not limited to , | 21 | | THJ-018, THJ-2201; | 22 | | (65) 2-(1-naphthoyl)benzimidazole with | 23 | | substitution at the nitrogen atom of the benzimidazole | 24 | | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 25 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 26 | | 1-(N-methyl-2-piperidinyl)methyl, or |
| | | HB2534 Enrolled | - 19 - | LRB100 08419 RLC 18533 b |
|
| 1 | | 2-(4-morpholinyl)ethyl, whether or not further | 2 | | substituted on the benzimidazole ring to any extent, | 3 | | whether or not substituted on the naphthyl ring to | 4 | | any extent: including, but not limited to , FUBIMINA; | 5 | | (66) N-(1-amino-3-methyl-1-oxobutan-2-yl) | 6 | | -1H-indazole-3-carboxamide with substitution on the | 7 | | nitrogen atom of the indazole ring by alkyl, | 8 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 9 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2- | 10 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 11 | | whether or not further substituted on the indazole | 12 | | ring to any extent: including , but not limited to , | 13 | | AB-PINACA, AB-FUBINACA, AB-CHMINACA; | 14 | | (67) N-(1-amino-3,3-dimethyl-1-oxobutan- | 15 | | 2-yl)-1H-indazole-3-carboxamide with substitution | 16 | | on the nitrogen atom of the indazole ring by alkyl, | 17 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 18 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2- | 19 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether | 20 | | or not further substituted on the indazole ring to any | 21 | | extent: including , but not limited to , ADB-PINACA, | 22 | | ADB-FUBINACA; | 23 | | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- | 24 | | 1H-indole-3-carboxamide with substitution on the nitrogen | 25 | | atom of the indole ring by alkyl, haloalkyl, alkenyl, | 26 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl |
| | | HB2534 Enrolled | - 20 - | LRB100 08419 RLC 18533 b |
|
| 1 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 2 | | 2-(4-morpholinyl)ethyl, whether or not further | 3 | | substituted on the indole ring to any extent: | 4 | | including , but not limited to , ADBICA, 5F-ADBICA; | 5 | | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)- | 6 | | 1H-indole-3-carboxamide with substitution on the | 7 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 8 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 9 | | halide, alkyl aryl halide, 1-(N-methyl-2- | 10 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 11 | | whether or not further substituted on the indole | 12 | | ring to any extent: including , but not limited | 13 | | to , ABICA, 5F-ABICA; | 14 | | (70) Methyl 2-(1H-indazole-3-carboxamido)- | 15 | | 3-methylbutanoate with substitution on the nitrogen | 16 | | atom of the indazole ring by alkyl, haloalkyl, | 17 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl | 18 | | halide, alkyl aryl halide, 1-(N-methyl-2- | 19 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, | 20 | | whether or not further substituted on the indazole | 21 | | ring to any extent: including , but not limited to , AMB, | 22 | | 5F-AMB. | 23 | | (71) Methyl 2-(1H-indazole-3-carboxamido)
| 24 | | -3,3-dimethylbutanoate with substitution on the nitrogen
| 25 | | atom of the indazole ring by alkyl, haloalkyl, alkenyl,
| 26 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
|
| | | HB2534 Enrolled | - 21 - | LRB100 08419 RLC 18533 b |
|
| 1 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-
| 2 | | (4-morpholinyl)ethyl, whether or not further substituted
| 3 | | on the indazole ring to any extent: including, but not
| 4 | | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | 5 | | (72) Methyl 2-(1H-indole-3-carboxamido)-
| 6 | | 3-methylbutanoate with substitution on the nitrogen atom
| 7 | | of the indole ring by alkyl, haloalkyl, alkenyl,
| 8 | | cycloalkylmethyl, cycloalkylethyl, aryl halide,
| 9 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
| 10 | | or 2-(4-morpholinyl)ethyl, whether or not further
| 11 | | substituted on the indazole ring to any extent:
| 12 | | including, but not limited to, MMB018, MMB2201,
| 13 | | and AMB-CHMICA; | 14 | | (73) Methyl 2-(1H-indole-3-
| 15 | | carboxamido)-3,3-dimethylbutanoate with substitution
| 16 | | on the nitrogen atom of the indole ring by alkyl,
| 17 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
| 18 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2-
| 19 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
| 20 | | whether or not further substituted on the
| 21 | | indazole ring to any extent: including, but
| 22 | | not limited to, MDMB-CHMICA; | 23 | | (74) N-(1-Amino-1-oxo-3-phenylpropan
| 24 | | -2-yl) -1H-indazole-3-carboxamide with
| 25 | | substitution on the nitrogen atom of the indazole
| 26 | | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
|
| | | HB2534 Enrolled | - 22 - | LRB100 08419 RLC 18533 b |
|
| 1 | | cycloalkylethyl, aryl halide, alkyl aryl halide,
| 2 | | 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-
| 3 | | morpholinyl)ethyl, whether or not further
| 4 | | substituted on the indazole ring to any
| 5 | | extent: including, but not limited to, APP-CHMINACA,
| 6 | | 5-fluoro-APP-PINACA; | 7 | | (75) N-(1-Amino-1-oxo-3-phenylpropan
| 8 | | -2-yl)-1H-indole-3-carboxamide with substitution on
| 9 | | the nitrogen atom of the indole ring by alkyl,
| 10 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
| 11 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2-
| 12 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
| 13 | | whether or not further substituted on the indazole
| 14 | | ring to any extent: including, but not limited to,
| 15 | | APP-PICA and 5-fluoro-APP-PICA; | 16 | | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | 17 | | 4-AcO-DMT; | 18 | | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: Trade | 19 | | name 5-MeO-MIPT; | 20 | | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | 21 | | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | 22 | | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | 23 | | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
| 24 | | (4-HO-MiPT); | 25 | | (82) Fluorophenylpiperazine; | 26 | | (83) Methoxetamine; |
| | | HB2534 Enrolled | - 23 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (84) 1-(Ethylamino)-2-phenylpropan-2-
| 2 | | one (iso-ethcathinone). | 3 | | (e) Unless specifically excepted or unless listed in | 4 | | another
schedule, any material, compound, mixture, or | 5 | | preparation which contains
any quantity of the following | 6 | | substances having a depressant effect on
the central nervous | 7 | | system, including its salts, isomers, and salts of
isomers | 8 | | whenever the existence of such salts, isomers, and salts of
| 9 | | isomers is possible within the specific chemical designation: | 10 | | (1) mecloqualone; | 11 | | (2) methaqualone; and | 12 | | (3) gamma hydroxybutyric acid. | 13 | | (f) Unless specifically excepted or unless listed in | 14 | | another schedule,
any material, compound, mixture, or | 15 | | preparation which contains any quantity
of the following | 16 | | substances having a stimulant effect on the central nervous
| 17 | | system, including its salts, isomers, and salts of isomers: | 18 | | (1) Fenethylline; | 19 | | (2) N-ethylamphetamine; | 20 | | (3) Aminorex (some other names:
| 21 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 22 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| 23 | | salts, optical isomers, and salts of optical isomers; | 24 | | (4) Methcathinone (some other names:
| 25 | | 2-methylamino-1-phenylpropan-1-one;
| 26 | | Ephedrone; 2-(methylamino)-propiophenone;
|
| | | HB2534 Enrolled | - 24 - | LRB100 08419 RLC 18533 b |
|
| 1 | | alpha-(methylamino)propiophenone; N-methylcathinone;
| 2 | | methycathinone; Monomethylpropion; UR 1431) and its
| 3 | | salts, optical isomers, and salts of optical isomers; | 4 | | (5) Cathinone (some trade or other names:
| 5 | | 2-aminopropiophenone; alpha-aminopropiophenone;
| 6 | | 2-amino-1-phenyl-propanone; norephedrone); | 7 | | (6) N,N-dimethylamphetamine (also known as:
| 8 | | N,N-alpha-trimethyl-benzeneethanamine;
| 9 | | N,N-alpha-trimethylphenethylamine); | 10 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 11 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | 12 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV) ; . | 13 | | (9) Halogenated amphetamines and
| 14 | | methamphetamines – any compound derived from either
| 15 | | amphetamine or methamphetamine through the substitution
| 16 | | of a halogen on the phenyl ring, including, but not
| 17 | | limited to, 2-fluoroamphetamine, 3-
| 18 | | fluoroamphetamine and 4-fluoroamphetamine; | 19 | | (10) Aminopropylbenzofuran (APB):
| 20 | | including 4-(2-Aminopropyl) benzofuran, 5-
| 21 | | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| 22 | | benzofuran, and 7-(2-Aminopropyl) benzofuran; | 23 | | (11) Aminopropyldihydrobenzofuran (APDB):
| 24 | | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| 25 | | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| 26 | | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
|
| | | HB2534 Enrolled | - 25 - | LRB100 08419 RLC 18533 b |
|
| 1 | | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | 2 | | (12) Methylaminopropylbenzofuran
| 3 | | (MAPB): including 4-(2-methylaminopropyl)
| 4 | | benzofuran, 5-(2-methylaminopropyl)benzofuran,
| 5 | | 6-(2-methylaminopropyl)benzofuran
| 6 | | and 7-(2-methylaminopropyl)benzofuran. | 7 | | (g) Temporary listing of substances subject to emergency | 8 | | scheduling.
Any material, compound, mixture, or preparation | 9 | | that contains any quantity
of the following substances: | 10 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| 11 | | (benzylfentanyl), its optical isomers, isomers, salts,
| 12 | | and salts of isomers; | 13 | | (2) N-[1(2-thienyl)
| 14 | | methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
| 15 | | its optical isomers, salts, and salts of isomers. | 16 | | (h) Synthetic cathinones. Unless specifically excepted, | 17 | | any chemical compound which is not approved by the United | 18 | | States Food and Drug Administration or, if approved, is not | 19 | | dispensed or possessed in accordance with State or federal law, | 20 | | not including bupropion, structurally derived from | 21 | | 2-aminopropan-1-one by substitution at the 1-position with | 22 | | either phenyl, naphthyl, or thiophene ring systems, whether or | 23 | | not the compound is further modified in one or more of the | 24 | | following ways: | 25 | | (1) by substitution in the ring system to | 26 | | any extent with alkyl, alkylenedioxy, alkoxy, |
| | | HB2534 Enrolled | - 26 - | LRB100 08419 RLC 18533 b |
|
| 1 | | haloalkyl, hydroxyl, or halide substituents, whether | 2 | | or not further substituted in the ring system | 3 | | by one or more other univalent substituents. | 4 | | Examples of this class include, but are not | 5 | | limited to, 3,4-Methylenedioxycathinone | 6 | | (bk-MDA); | 7 | | (2) by substitution at the 3-position | 8 | | with an acyclic alkyl substituent. Examples of | 9 | | this class include, but are not limited to, | 10 | | 2-methylamino-1-phenylbutan-1-one | 11 | | (buphedrone); or | 12 | | (3) by substitution at the 2-amino nitrogen | 13 | | atom with alkyl, dialkyl, benzyl, or methoxybenzyl | 14 | | groups, or by inclusion of the 2-amino nitrogen atom | 15 | | in a cyclic structure. Examples of this class include, | 16 | | but are not limited to, Dimethylcathinone, Ethcathinone, | 17 | | and a-Pyrrolidinopropiophenone (a-PPP). | 18 | | (Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised | 19 | | 10-25-16.)
| 20 | | (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
| 21 | | Sec. 206. (a) The controlled substances listed in this | 22 | | Section are
included in Schedule II.
| 23 | | (b) Unless specifically excepted or unless listed in | 24 | | another
schedule, any of the following substances whether | 25 | | produced directly or
indirectly by extraction from substances |
| | | HB2534 Enrolled | - 27 - | LRB100 08419 RLC 18533 b |
|
| 1 | | of vegetable origin, or
independently by means of chemical | 2 | | synthesis, or by combination of
extraction and chemical | 3 | | synthesis:
| 4 | | (1) Opium and opiates, and any salt, compound, | 5 | | derivative or
preparation of opium or opiate, excluding | 6 | | apomorphine, dextrorphan,
levopropoxyphene,
nalbuphine, | 7 | | nalmefene, naloxone, and naltrexone, and their respective
| 8 | | salts, but including the following:
| 9 | | (i) Raw Opium;
| 10 | | (ii) Opium extracts;
| 11 | | (iii) Opium fluid extracts;
| 12 | | (iv) Powdered opium;
| 13 | | (v) Granulated opium;
| 14 | | (vi) Tincture of opium;
| 15 | | (vii) Codeine;
| 16 | | (viii) Ethylmorphine;
| 17 | | (ix) Etorphine Hydrochloride;
| 18 | | (x) Hydrocodone;
| 19 | | (xi) Hydromorphone;
| 20 | | (xii) Metopon;
| 21 | | (xiii) Morphine;
| 22 | | (xiii.5) 6-Monoacetylmorphine;
| 23 | | (xiv) Oxycodone;
| 24 | | (xv) Oxymorphone;
| 25 | | (xv.5) Tapentadol;
| 26 | | (xvi) Thebaine;
|
| | | HB2534 Enrolled | - 28 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (xvii) Thebaine-derived butorphanol.
| 2 | | (xviii) Methorphan Dextromethorphan , except drug | 3 | | products containing dextromethorphan that may be | 4 | | dispensed pursuant to a prescription order of a | 5 | | practitioner and are sold in compliance with the safety | 6 | | and labeling standards as set forth by the United | 7 | | States Food and Drug Administration, or drug products | 8 | | containing dextromethorphan that are sold in solid, | 9 | | tablet, liquid, capsule, powder, thin film, or gel form | 10 | | and which are formulated, packaged, and sold in dosages | 11 | | and concentrations for use as an over-the-counter drug | 12 | | product. For the purposes of this Section, | 13 | | "over-the-counter drug product" means a drug that is | 14 | | available to consumers without a prescription and sold | 15 | | in compliance with the safety and labeling standards as | 16 | | set forth by the United States Food and Drug | 17 | | Administration.
| 18 | | (2) Any salt, compound, isomer, derivative or | 19 | | preparation thereof
which is chemically equivalent or | 20 | | identical with any of the substances
referred to in | 21 | | subparagraph (1), but not including the isoquinoline
| 22 | | alkaloids of opium;
| 23 | | (3) Opium poppy and poppy straw;
| 24 | | (4) Coca leaves and any salt, compound, isomer, salt of | 25 | | an isomer,
derivative, or preparation of coca leaves | 26 | | including cocaine or ecgonine,
and any salt, compound, |
| | | HB2534 Enrolled | - 29 - | LRB100 08419 RLC 18533 b |
|
| 1 | | isomer, derivative, or preparation thereof which is
| 2 | | chemically equivalent or identical with any of these | 3 | | substances, but not
including decocainized coca leaves or | 4 | | extractions of coca leaves which do
not contain cocaine or | 5 | | ecgonine (for the purpose of this paragraph, the
term | 6 | | "isomer" includes optical, positional and geometric | 7 | | isomers);
| 8 | | (5) Concentrate of poppy straw (the crude extract of | 9 | | poppy straw in
either liquid, solid or powder form which | 10 | | contains the phenanthrine
alkaloids of the opium poppy).
| 11 | | (c) Unless specifically excepted or unless listed in | 12 | | another
schedule any of the following opiates, including their | 13 | | isomers, esters,
ethers, salts, and salts of isomers, whenever | 14 | | the existence of these
isomers, esters, ethers and salts is | 15 | | possible within the specific
chemical designation, dextrorphan | 16 | | excepted:
| 17 | | (1) Alfentanil;
| 18 | | (1.1) Carfentanil;
| 19 | | (1.2) Thiafentanyl;
| 20 | | (2) Alphaprodine;
| 21 | | (3) Anileridine;
| 22 | | (4) Bezitramide;
| 23 | | (5) Bulk Dextropropoxyphene (non-dosage forms);
| 24 | | (6) Dihydrocodeine;
| 25 | | (7) Diphenoxylate;
| 26 | | (8) Fentanyl;
|
| | | HB2534 Enrolled | - 30 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (9) Sufentanil;
| 2 | | (9.5) Remifentanil;
| 3 | | (10) Isomethadone;
| 4 | | (11) (Blank); Levomethorphan;
| 5 | | (12) Levorphanol (Levorphan);
| 6 | | (13) Metazocine;
| 7 | | (14) Methadone;
| 8 | | (15) Methadone-Intermediate,
| 9 | | 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
| 10 | | (16) Moramide-Intermediate,
| 11 | | 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
| 12 | | acid;
| 13 | | (17) Pethidine (meperidine);
| 14 | | (18) Pethidine-Intermediate-A,
| 15 | | 4-cyano-1-methyl-4-phenylpiperidine;
| 16 | | (19) Pethidine-Intermediate-B,
| 17 | | ethyl-4-phenylpiperidine-4-carboxylate;
| 18 | | (20) Pethidine-Intermediate-C,
| 19 | | 1-methyl-4-phenylpiperidine-4-carboxylic acid;
| 20 | | (21) Phenazocine;
| 21 | | (22) Piminodine;
| 22 | | (23) Racemethorphan;
| 23 | | (24) (Blank); Racemorphan;
| 24 | | (25) Levo-alphacetylmethadol (some other names:
| 25 | | levo-alpha-acetylmethadol,
levomethadyl acetate, LAAM).
| 26 | | (d) Unless specifically excepted or unless listed in |
| | | HB2534 Enrolled | - 31 - | LRB100 08419 RLC 18533 b |
|
| 1 | | another
schedule, any material, compound, mixture, or | 2 | | preparation which contains
any quantity of the following | 3 | | substances having a stimulant effect on
the central nervous | 4 | | system:
| 5 | | (1) Amphetamine, its salts, optical isomers, and salts | 6 | | of its
optical isomers;
| 7 | | (2) Methamphetamine, its salts, isomers, and salts of | 8 | | its isomers;
| 9 | | (3) Phenmetrazine and its salts;
| 10 | | (4) Methylphenidate;
| 11 | | (5) Lisdexamfetamine. | 12 | | (e) Unless specifically excepted or unless listed in | 13 | | another
schedule, any material, compound, mixture, or | 14 | | preparation which contains
any quantity of the following | 15 | | substances having a depressant effect on
the central nervous | 16 | | system, including its salts, isomers, and salts of
isomers | 17 | | whenever the existence of such salts, isomers, and salts of
| 18 | | isomers is possible within the specific chemical designation:
| 19 | | (1) Amobarbital;
| 20 | | (2) Secobarbital;
| 21 | | (3) Pentobarbital;
| 22 | | (4) Pentazocine;
| 23 | | (5) Phencyclidine;
| 24 | | (6) Gluthethimide;
| 25 | | (7) (Blank).
| 26 | | (f) Unless specifically excepted or unless listed in |
| | | HB2534 Enrolled | - 32 - | LRB100 08419 RLC 18533 b |
|
| 1 | | another schedule,
any material, compound, mixture, or | 2 | | preparation which contains any quantity
of the following | 3 | | substances:
| 4 | | (1) Immediate precursor to amphetamine and | 5 | | methamphetamine:
| 6 | | (i) Phenylacetone
| 7 | | Some trade or other names: phenyl-2-propanone;
| 8 | | P2P; benzyl methyl ketone; methyl benzyl ketone.
| 9 | | (2) Immediate precursors to phencyclidine:
| 10 | | (i) 1-phenylcyclohexylamine;
| 11 | | (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
| 12 | | (3) Nabilone.
| 13 | | (Source: P.A. 97-334, eff. 1-1-12.)
| 14 | | (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
| 15 | | Sec. 208.
(a) The controlled substances listed in this | 16 | | Section are
included in Schedule III.
| 17 | | (b) Unless specifically excepted or unless listed in | 18 | | another
schedule, any material, compound, mixture, or | 19 | | preparation which contains
any quantity of the following | 20 | | substances having a stimulant effect on
the central nervous | 21 | | system, including its salts, isomers (whether
optical | 22 | | position, or geometric), and salts of such isomers whenever the
| 23 | | existence of such salts, isomers, and salts of isomers is | 24 | | possible
within the specific chemical designation;
| 25 | | (1) Those compounds, mixtures, or preparations in |
| | | HB2534 Enrolled | - 33 - | LRB100 08419 RLC 18533 b |
|
| 1 | | dosage unit form
containing any stimulant substances | 2 | | listed in Schedule II which
compounds, mixtures, or | 3 | | preparations were listed on August 25, 1971, as
excepted | 4 | | compounds under Title 21, Code of Federal Regulations, | 5 | | Section
308.32, and any other drug of the quantitative | 6 | | composition shown in that
list for those drugs or which is | 7 | | the same except that it contains a
lesser quantity of | 8 | | controlled substances;
| 9 | | (2) Benzphetamine;
| 10 | | (3) Chlorphentermine;
| 11 | | (4) Clortermine;
| 12 | | (5) Phendimetrazine.
| 13 | | (c) Unless specifically excepted or unless listed in | 14 | | another
schedule, any material, compound, mixture, or | 15 | | preparation which contains
any quantity of the following | 16 | | substances having a potential for abuse
associated with a | 17 | | depressant effect on the central nervous system:
| 18 | | (1) Any compound, mixture, or preparation containing | 19 | | amobarbital,
secobarbital, pentobarbital or any salt | 20 | | thereof and one or more other
active medicinal ingredients | 21 | | which are not listed in any schedule;
| 22 | | (2) Any suppository dosage form containing | 23 | | amobarbital,
secobarbital, pentobarbital or any salt of | 24 | | any of these drugs and
approved by the Federal Food and | 25 | | Drug Administration for marketing only
as a suppository;
| 26 | | (3) Any substance which contains any quantity of a |
| | | HB2534 Enrolled | - 34 - | LRB100 08419 RLC 18533 b |
|
| 1 | | derivative of
barbituric acid, or any salt thereof:
| 2 | | (3.1) Aprobarbital; | 3 | | (3.2) Butabarbital (secbutabarbital); | 4 | | (3.3) Butalbital; | 5 | | (3.4) Butobarbital (butethal);
| 6 | | (4) Chlorhexadol;
| 7 | | (5) Methyprylon;
| 8 | | (6) Sulfondiethylmethane;
| 9 | | (7) Sulfonethylmethane;
| 10 | | (8) Sulfonmethane;
| 11 | | (9) Lysergic acid;
| 12 | | (10) Lysergic acid amide;
| 13 | | (10.1) Tiletamine or zolazepam or both, or any salt of | 14 | | either of them.
| 15 | | Some trade or other names for a tiletamine-zolazepam
| 16 | | combination product: Telazol.
| 17 | | Some trade or other names for Tiletamine:
| 18 | | 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
| 19 | | Some trade or other names for zolazepam:
| 20 | | 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
| 21 | | [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
| 22 | | (11) Any material, compound, mixture or preparation | 23 | | containing not more
than 12.5 milligrams of pentazocine or | 24 | | any of its salts, per 325 milligrams of
aspirin;
| 25 | | (12) Any material, compound, mixture or preparation | 26 | | containing not
more than 12.5 milligrams of pentazocine or |
| | | HB2534 Enrolled | - 35 - | LRB100 08419 RLC 18533 b |
|
| 1 | | any of its salts, per 325
milligrams of acetaminophen;
| 2 | | (13) Any material, compound, mixture or preparation | 3 | | containing not more
than 50 milligrams of pentazocine or | 4 | | any of its salts plus naloxone HCl USP
0.5 milligrams, per | 5 | | dosage unit;
| 6 | | (14) Ketamine;
| 7 | | (15) Thiopental. | 8 | | (d) Nalorphine.
| 9 | | (d.5) Buprenorphine. | 10 | | (e) Unless specifically excepted or unless listed in | 11 | | another
schedule, any material, compound, mixture, or | 12 | | preparation containing
limited quantities of any of the | 13 | | following narcotic drugs, or their salts
calculated as the free | 14 | | anhydrous base or alkaloid, as set forth below:
| 15 | | (1) not more than 1.8 grams of codeine per 100
| 16 | | milliliters or not more than 90 milligrams per dosage unit, | 17 | | with an
equal or greater quantity of an isoquinoline | 18 | | alkaloid of opium;
| 19 | | (2) not more than 1.8 grams of codeine per 100
| 20 | | milliliters or not more than 90 milligrams per dosage unit, | 21 | | with one or
more active non-narcotic ingredients in | 22 | | recognized therapeutic amounts;
| 23 | | (3) (blank); not more than 300 milligrams of | 24 | | dihydrocodeinone per 100 milliliters
or not more than 15 | 25 | | milligrams per dosage
unit, with a fourfold or greater | 26 | | quantity of an isoquinoline alkaloid of
opium;
|
| | | HB2534 Enrolled | - 36 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (4) (blank); not more than 300 milligrams of | 2 | | dihydrocodeinone per 100 milliliters
or not more than 15 | 3 | | milligrams per dosage
unit, with one or more active, | 4 | | non-narcotic ingredients in recognized
therapeutic | 5 | | amounts;
| 6 | | (5) not more than 1.8 grams of dihydrocodeine
per 100 | 7 | | milliliters or not more than 90 milligrams per dosage unit, | 8 | | with
one or more active, non-narcotic ingredients in | 9 | | recognized therapeutic
amounts;
| 10 | | (6) not more than 300 milligrams of ethylmorphine per | 11 | | 100 milliliters
or not more than 15 milligrams per dosage
| 12 | | unit, with one or more active, non-narcotic ingredients in | 13 | | recognized
therapeutic amounts;
| 14 | | (7) not more than 500 milligrams of opium per 100 | 15 | | milliliters or per
100 grams, or not more than 25 | 16 | | milligrams per dosage unit, with one or
more active, | 17 | | non-narcotic ingredients in recognized therapeutic | 18 | | amounts;
| 19 | | (8) not more than 50 milligrams of morphine
per 100 | 20 | | milliliters or per 100 grams with one or more active,
| 21 | | non-narcotic ingredients in recognized therapeutic | 22 | | amounts.
| 23 | | (f) Anabolic steroids, except the following anabolic | 24 | | steroids that are
exempt:
| 25 | | (1) Androgyn L.A.;
| 26 | | (2) Andro-Estro 90-4;
|
| | | HB2534 Enrolled | - 37 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (3) depANDROGYN;
| 2 | | (4) DEPO-T.E.;
| 3 | | (5) depTESTROGEN;
| 4 | | (6) Duomone;
| 5 | | (7) DURATESTRIN;
| 6 | | (8) DUO-SPAN II;
| 7 | | (9) Estratest;
| 8 | | (10) Estratest H.S.;
| 9 | | (11) PAN ESTRA TEST;
| 10 | | (12) Premarin with Methyltestosterone;
| 11 | | (13) TEST-ESTRO Cypionates;
| 12 | | (14) Testosterone Cyp 50 Estradiol Cyp 2;
| 13 | | (15) Testosterone Cypionate-Estradiol Cypionate | 14 | | injection; and
| 15 | | (16) Testosterone Enanthate-Estradiol Valerate | 16 | | injection.
| 17 | | (g) Hallucinogenic
substances.
| 18 | | (1) Dronabinol (synthetic) in sesame oil and | 19 | | encapsulated in a soft
gelatin capsule in a U.S.
Food and | 20 | | Drug Administration approved product. Some other names for
| 21 | | dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
| 22 | | 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)
pyran-1-ol) or | 23 | | (-)-delta-9-(trans)-tetrahydrocannabinol.
| 24 | | (2) (Reserved).
| 25 | | (h) The Department may except by rule any compound, | 26 | | mixture, or
preparation containing any stimulant or depressant |
| | | HB2534 Enrolled | - 38 - | LRB100 08419 RLC 18533 b |
|
| 1 | | substance listed in
subsection (b) from the application of all | 2 | | or any part of this
Act if the compound, mixture, or | 3 | | preparation contains one or more active
medicinal ingredients | 4 | | not having a stimulant or depressant effect on the
central | 5 | | nervous system, and if the admixtures are included therein in
| 6 | | combinations, quantity, proportion, or concentration that | 7 | | vitiate the
potential for abuse of the substances which have a | 8 | | stimulant or
depressant effect on the central nervous system.
| 9 | | (Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10; | 10 | | 97-334, eff. 1-1-12.)
| 11 | | (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)
| 12 | | Sec. 401. Manufacture or delivery, or possession with | 13 | | intent to
manufacture or deliver, a controlled substance, a | 14 | | counterfeit substance, or controlled substance analog. Except | 15 | | as authorized by this Act, it is unlawful for any
person | 16 | | knowingly to manufacture or deliver, or possess with intent to
| 17 | | manufacture or deliver, a controlled substance other than | 18 | | methamphetamine and other than bath salts as defined in the | 19 | | Bath Salts Prohibition Act sold or offered for sale in a retail | 20 | | mercantile establishment as defined in Section 16-0.1 of the | 21 | | Criminal Code of 2012, a counterfeit substance, or a controlled
| 22 | | substance analog. A violation of this Act with respect to each | 23 | | of the controlled
substances listed herein constitutes a single | 24 | | and separate violation of this
Act. For purposes of this | 25 | | Section, "controlled substance analog" or "analog"
means a |
| | | HB2534 Enrolled | - 39 - | LRB100 08419 RLC 18533 b |
|
| 1 | | substance, other than a controlled substance, which is not | 2 | | approved by the United States Food and Drug Administration or, | 3 | | if approved, is not dispensed or possessed in accordance with | 4 | | State or federal law, and that has a chemical structure | 5 | | substantially similar to that of a controlled
substance in | 6 | | Schedule I or II, or that was specifically designed to produce
| 7 | | an effect substantially similar to that of a controlled | 8 | | substance in Schedule
I or II. Examples of chemical classes in | 9 | | which controlled substance analogs
are found include, but are | 10 | | not limited to, the following: phenethylamines,
N-substituted | 11 | | piperidines, morphinans, ecgonines, quinazolinones, | 12 | | substituted
indoles, and arylcycloalkylamines. For purposes of | 13 | | this Act, a controlled
substance analog shall be treated in the | 14 | | same manner as the controlled
substance to which it is | 15 | | substantially similar.
| 16 | | (a) Any person who violates this Section with respect to | 17 | | the following
amounts of controlled or counterfeit substances | 18 | | or controlled substance
analogs, notwithstanding any of the | 19 | | provisions of subsections (c),
(d), (e), (f), (g) or (h) to the | 20 | | contrary, is guilty of a Class X felony
and shall be sentenced | 21 | | to a term of imprisonment as provided in this subsection
(a) | 22 | | and fined as provided in subsection (b):
| 23 | | (1) (A) not less than 6 years and not more than 30 | 24 | | years with respect
to 15 grams or more but less than | 25 | | 100 grams of a substance containing
heroin, or an | 26 | | analog thereof;
|
| | | HB2534 Enrolled | - 40 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (B) not less than 9 years and not more than 40 | 2 | | years with respect to 100
grams or more but less than | 3 | | 400 grams of a substance containing heroin, or
an | 4 | | analog thereof;
| 5 | | (C) not less than 12 years and not more than 50 | 6 | | years with respect to
400 grams or more but less than | 7 | | 900 grams of a substance containing heroin,
or an | 8 | | analog thereof;
| 9 | | (D) not less than 15 years and not more than 60 | 10 | | years with respect to
900 grams or more of any | 11 | | substance containing heroin, or an analog thereof;
| 12 | | (1.5) (A) not less than 6 years and not more than 30 | 13 | | years with respect to 15 grams or more but less than | 14 | | 100 grams of a substance containing fentanyl, or an | 15 | | analog thereof; | 16 | | (B) not less than 9 years and not more than 40 | 17 | | years with respect to 100 grams or more but less than | 18 | | 400 grams of a substance containing fentanyl, or an | 19 | | analog thereof; | 20 | | (C) not less than 12 years and not more than 50 | 21 | | years with respect to 400 grams or more but less than | 22 | | 900 grams of a substance containing fentanyl, or an | 23 | | analog thereof; | 24 | | (D) not less than 15 years and not more than 60 | 25 | | years with respect to 900 grams or more of a substance | 26 | | containing fentanyl, or an analog thereof; |
| | | HB2534 Enrolled | - 41 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (2) (A) not less than 6 years and not more than 30 | 2 | | years with respect
to 15 grams or more but less than | 3 | | 100 grams of a substance containing
cocaine, or an | 4 | | analog thereof;
| 5 | | (B) not less than 9 years and not more than 40 | 6 | | years with respect to 100
grams or more but less than | 7 | | 400 grams of a substance containing cocaine, or
an | 8 | | analog thereof;
| 9 | | (C) not less than 12 years and not more than 50 | 10 | | years with respect to
400 grams or more but less than | 11 | | 900 grams of a substance containing cocaine,
or an | 12 | | analog thereof;
| 13 | | (D) not less than 15 years and not more than 60 | 14 | | years with respect to
900 grams or more of any | 15 | | substance containing cocaine, or an analog thereof;
| 16 | | (3) (A) not less than 6 years and not more than 30 | 17 | | years with respect
to 15 grams or more but less than | 18 | | 100 grams of a substance containing
morphine, or an | 19 | | analog thereof;
| 20 | | (B) not less than 9 years and not more than 40 | 21 | | years with respect to
100 grams or more but less than | 22 | | 400 grams of a substance containing morphine,
or an | 23 | | analog thereof;
| 24 | | (C) not less than 12 years and not more than 50 | 25 | | years with respect to
400 grams or more but less than | 26 | | 900 grams of a substance containing
morphine, or an |
| | | HB2534 Enrolled | - 42 - | LRB100 08419 RLC 18533 b |
|
| 1 | | analog thereof;
| 2 | | (D) not less than 15 years and not more than 60 | 3 | | years with respect to
900 grams or more of a substance | 4 | | containing morphine, or an analog thereof;
| 5 | | (4) 200 grams or more of any substance containing | 6 | | peyote, or an
analog thereof;
| 7 | | (5) 200 grams or more of any substance containing a | 8 | | derivative of
barbituric acid or any of the salts of a | 9 | | derivative of barbituric acid, or
an analog thereof;
| 10 | | (6) 200 grams or more of any substance containing | 11 | | amphetamine
or any salt of an optical isomer of | 12 | | amphetamine,
or an analog thereof;
| 13 | | (6.5) (blank);
| 14 | | (6.6) (blank);
| 15 | | (7) (A) not less than 6 years and not more than 30 | 16 | | years with respect
to: (i) 15 grams or more but less | 17 | | than 100 grams of a substance containing
lysergic acid | 18 | | diethylamide (LSD), or an analog thereof, or (ii) 15 or
| 19 | | more objects or 15 or more segregated parts of an | 20 | | object or objects but
less than 200 objects or 200 | 21 | | segregated parts of an object or objects
containing in | 22 | | them or having upon them any amounts of any substance
| 23 | | containing lysergic acid diethylamide (LSD), or an | 24 | | analog thereof;
| 25 | | (B) not less than 9 years and not more than 40 | 26 | | years with respect
to: (i) 100 grams or more but less |
| | | HB2534 Enrolled | - 43 - | LRB100 08419 RLC 18533 b |
|
| 1 | | than 400 grams of a substance containing
lysergic acid | 2 | | diethylamide (LSD), or an analog thereof, or (ii) 200 | 3 | | or more
objects or 200 or more segregated parts of an | 4 | | object or objects but less
than 600 objects or less | 5 | | than 600 segregated parts of an object or objects
| 6 | | containing in them or having upon them any amount of | 7 | | any substance
containing lysergic acid diethylamide | 8 | | (LSD), or an analog thereof;
| 9 | | (C) not less than 12 years and not more than 50 | 10 | | years with respect
to: (i) 400 grams or more but less | 11 | | than 900 grams of a substance containing
lysergic acid | 12 | | diethylamide (LSD), or an analog thereof, or (ii) 600 | 13 | | or more
objects or 600 or more segregated parts of an | 14 | | object or objects but less
than 1500 objects or 1500 | 15 | | segregated parts of an object or objects
containing in | 16 | | them or having upon them any amount of any substance
| 17 | | containing lysergic acid diethylamide (LSD), or an | 18 | | analog thereof;
| 19 | | (D) not less than 15 years and not more than 60 | 20 | | years with respect
to: (i) 900 grams or more of any | 21 | | substance containing lysergic acid
diethylamide (LSD), | 22 | | or an analog thereof, or (ii) 1500 or more objects or
| 23 | | 1500 or more segregated parts of an object or objects | 24 | | containing in them or
having upon them any amount of a | 25 | | substance containing lysergic acid
diethylamide (LSD), | 26 | | or an analog thereof;
|
| | | HB2534 Enrolled | - 44 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (7.5) (A) not less than 6 years and not more than 30 | 2 | | years with respect
to:
(i) 15
grams or more but less | 3 | | than 100 grams of a substance listed in paragraph (1),
| 4 | | (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), | 5 | | (21), (25), or (26) of subsection
(d) of Section 204, | 6 | | or an analog or derivative thereof, or (ii) 15 or more
| 7 | | pills, tablets, caplets, capsules, or objects but less | 8 | | than 200 pills, tablets,
caplets, capsules, or objects | 9 | | containing in them or having upon them any
amounts of | 10 | | any substance listed in paragraph (1), (2), (2.1), | 11 | | (2.2), (3), (14.1),
(19), (20), (20.1), (21), (25), or | 12 | | (26) of subsection (d) of Section 204, or
an analog or | 13 | | derivative thereof;
| 14 | | (B) not less than 9 years and not more than 40 | 15 | | years with respect to:
(i) 100 grams or more but less | 16 | | than 400 grams of a substance listed in
paragraph (1), | 17 | | (2), (2.1), (2.2), (3), (14.1), (19), (20),
(20.1), | 18 | | (21), (25), or (26) of subsection (d) of Section 204, | 19 | | or an analog or
derivative thereof, or (ii) 200 or more | 20 | | pills, tablets, caplets, capsules, or
objects but less | 21 | | than 600 pills, tablets, caplets, capsules, or objects
| 22 | | containing in them or having upon them any amount of | 23 | | any substance listed in
paragraph (1), (2), (2.1), | 24 | | (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or | 25 | | (26)
of subsection (d) of Section 204, or an analog or | 26 | | derivative thereof;
|
| | | HB2534 Enrolled | - 45 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (C) not less than 12 years and not more than 50 | 2 | | years with respect to:
(i) 400 grams or more but less | 3 | | than 900 grams of a substance listed in
paragraph (1), | 4 | | (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), | 5 | | (21), (25), or (26)
of subsection (d) of Section 204, | 6 | | or an analog or derivative thereof,
or (ii) 600 or more | 7 | | pills, tablets, caplets, capsules, or objects but less | 8 | | than
1,500 pills, tablets, caplets, capsules, or | 9 | | objects
containing in them or having upon them any | 10 | | amount of any substance listed in
paragraph (1), (2), | 11 | | (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21), | 12 | | (25), or (26)
of subsection (d) of Section 204, or an | 13 | | analog or derivative thereof;
| 14 | | (D) not less than 15 years and not more than 60 | 15 | | years with respect to:
(i) 900 grams or more of any | 16 | | substance listed in paragraph (1), (2), (2.1),
(2.2), | 17 | | (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of | 18 | | subsection (d) of
Section 204, or an analog or | 19 | | derivative thereof, or (ii) 1,500 or more pills,
| 20 | | tablets, caplets, capsules, or objects containing in | 21 | | them or having upon them
any amount
of a substance | 22 | | listed in paragraph (1), (2), (2.1), (2.2), (3), | 23 | | (14.1), (19),
(20), (20.1), (21), (25), or (26)
of | 24 | | subsection (d) of Section 204, or an analog or | 25 | | derivative thereof;
| 26 | | (8) 30 grams or more of any substance containing |
| | | HB2534 Enrolled | - 46 - | LRB100 08419 RLC 18533 b |
|
| 1 | | pentazocine or any of
the salts, isomers and salts of | 2 | | isomers of pentazocine, or an analog thereof;
| 3 | | (9) 30 grams or more of any substance containing | 4 | | methaqualone or any of
the salts, isomers and salts of | 5 | | isomers of methaqualone, or an analog thereof;
| 6 | | (10) 30 grams or more of any substance containing | 7 | | phencyclidine or any
of the salts, isomers and salts of | 8 | | isomers of phencyclidine (PCP),
or an analog thereof;
| 9 | | (10.5) 30 grams or more of any substance containing | 10 | | ketamine
or any of the salts, isomers and salts of isomers | 11 | | of ketamine,
or an analog thereof;
| 12 | | (10.6) 100 grams or more of any substance containing | 13 | | hydrocodone, or any of the salts, isomers and salts of | 14 | | isomers of hydrocodone, or an analog thereof; | 15 | | (10.7) (blank); 100 grams or more of any substance | 16 | | containing dihydrocodeinone, or any of the salts, isomers | 17 | | and salts of isomers of dihydrocodeinone, or an analog | 18 | | thereof; | 19 | | (10.8) 100 grams or more of any substance containing | 20 | | dihydrocodeine, or any of the salts, isomers and salts of | 21 | | isomers of dihydrocodeine, or an analog thereof; | 22 | | (10.9) 100 grams or more of any substance containing | 23 | | oxycodone, or any of the salts, isomers and salts of | 24 | | isomers of oxycodone, or an analog thereof; | 25 | | (11) 200 grams or more of any substance containing any | 26 | | other controlled
substance classified in Schedules I or II, |
| | | HB2534 Enrolled | - 47 - | LRB100 08419 RLC 18533 b |
|
| 1 | | or an analog thereof, which is
not otherwise included in | 2 | | this subsection.
| 3 | | (b) Any person sentenced with respect to violations of | 4 | | paragraph (1),
(2), (3), (7), or (7.5) of subsection (a) | 5 | | involving
100 grams or
more of the
controlled substance named | 6 | | therein, may in addition to the penalties
provided therein, be | 7 | | fined an amount not more than $500,000 or the full
street value | 8 | | of the controlled or counterfeit substance or controlled | 9 | | substance
analog, whichever is greater. The term "street value" | 10 | | shall have the
meaning ascribed in Section 110-5 of the Code of | 11 | | Criminal Procedure of
1963. Any person sentenced with respect | 12 | | to any other provision of
subsection (a), may in addition to | 13 | | the penalties provided therein, be fined
an amount not to | 14 | | exceed $500,000. | 15 | | (b-1) Excluding violations of this Act when the controlled | 16 | | substance is fentanyl, any person sentenced to a term of | 17 | | imprisonment with respect to violations of Section 401, 401.1, | 18 | | 405, 405.1, 405.2, or 407, when the substance containing the | 19 | | controlled substance contains any amount of fentanyl, 3 years | 20 | | shall be added to the term of imprisonment imposed by the | 21 | | court, and the maximum sentence for the offense shall be | 22 | | increased by 3 years.
| 23 | | (c) Any person who violates this Section with regard to the
| 24 | | following amounts of controlled or counterfeit substances
or | 25 | | controlled substance analogs, notwithstanding any of the | 26 | | provisions of
subsections (a), (b), (d), (e), (f), (g) or (h) |
| | | HB2534 Enrolled | - 48 - | LRB100 08419 RLC 18533 b |
|
| 1 | | to the
contrary, is guilty of a Class 1 felony. The fine for | 2 | | violation of this
subsection (c) shall not be more than | 3 | | $250,000:
| 4 | | (1) 1 gram or more but less than 15 grams of any
| 5 | | substance containing heroin, or an analog thereof;
| 6 | | (1.5) 1 gram or more but less than 15 grams of any | 7 | | substance containing fentanyl, or an analog thereof; | 8 | | (2) 1 gram or more but less than 15
grams of any | 9 | | substance containing cocaine, or an analog thereof;
| 10 | | (3) 10 grams or more but less than 15 grams of any | 11 | | substance
containing morphine, or an analog thereof;
| 12 | | (4) 50 grams or more but less than 200 grams of any | 13 | | substance
containing peyote, or an analog thereof;
| 14 | | (5) 50 grams or more but less than 200 grams of any | 15 | | substance
containing a derivative of barbituric acid or any | 16 | | of the salts of a
derivative of barbituric acid, or an | 17 | | analog thereof;
| 18 | | (6) 50 grams or more but less than 200 grams of any | 19 | | substance
containing amphetamine or any salt of an optical | 20 | | isomer
of amphetamine, or an analog thereof;
| 21 | | (6.5) (blank);
| 22 | | (7) (i) 5 grams or more but less than 15 grams of any | 23 | | substance
containing lysergic acid diethylamide (LSD), or | 24 | | an analog thereof,
or (ii)
more than 10 objects or more | 25 | | than 10 segregated parts of an object or objects
but less | 26 | | than 15 objects or less than 15 segregated parts of an |
| | | HB2534 Enrolled | - 49 - | LRB100 08419 RLC 18533 b |
|
| 1 | | object
containing in them or having upon them any amount of | 2 | | any substance
containing lysergic acid diethylamide (LSD), | 3 | | or an analog thereof;
| 4 | | (7.5) (i) 5 grams or more but less than 15 grams of any | 5 | | substance listed
in paragraph (1), (2), (2.1), (2.2), (3), | 6 | | (14.1), (19), (20), (20.1), (21), (25), or
(26) of | 7 | | subsection (d) of Section 204, or an analog or derivative | 8 | | thereof, or
(ii) more than 10 pills, tablets, caplets, | 9 | | capsules, or objects but less than
15 pills, tablets, | 10 | | caplets, capsules, or objects containing in them or having
| 11 | | upon them any amount of any substance listed in paragraph | 12 | | (1), (2), (2.1),
(2.2), (3), (14.1), (19), (20), (20.1), | 13 | | (21), (25), or (26) of subsection (d) of
Section 204, or an | 14 | | analog or derivative thereof;
| 15 | | (8) 10 grams or more but less than 30 grams of any | 16 | | substance
containing pentazocine or any of the salts, | 17 | | isomers and salts of isomers of
pentazocine, or an analog | 18 | | thereof;
| 19 | | (9) 10 grams or more but less than 30 grams of any | 20 | | substance
containing methaqualone or any of the salts, | 21 | | isomers and salts of isomers
of methaqualone, or an analog | 22 | | thereof;
| 23 | | (10) 10 grams or more but less than 30 grams of any | 24 | | substance
containing phencyclidine or any of the salts, | 25 | | isomers and salts of isomers
of phencyclidine (PCP), or an | 26 | | analog thereof;
|
| | | HB2534 Enrolled | - 50 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (10.5) 10 grams or more but less than 30 grams of any | 2 | | substance
containing ketamine or any of the salts, isomers | 3 | | and salts of
isomers of ketamine, or an analog thereof;
| 4 | | (10.6) 50 grams or more but less than 100 grams of any | 5 | | substance containing hydrocodone, or any of the salts, | 6 | | isomers and salts of isomers of hydrocodone, or an analog | 7 | | thereof; | 8 | | (10.7) (blank); 50 grams or more but less than 100 | 9 | | grams of any substance containing dihydrocodeinone, or any | 10 | | of the salts, isomers and salts of isomers of | 11 | | dihydrocodeinone, or an analog thereof; | 12 | | (10.8) 50 grams or more but less than 100 grams of any | 13 | | substance containing dihydrocodeine, or any of the salts, | 14 | | isomers and salts of isomers of dihydrocodeine, or an | 15 | | analog thereof; | 16 | | (10.9) 50 grams or more but less than 100 grams of any | 17 | | substance containing oxycodone, or any of the salts, | 18 | | isomers and salts of isomers of oxycodone, or an analog | 19 | | thereof; | 20 | | (11) 50 grams or more but less than 200 grams of any | 21 | | substance
containing a substance classified in Schedules I | 22 | | or II, or an analog
thereof, which is not otherwise | 23 | | included in this subsection.
| 24 | | (c-5) (Blank).
| 25 | | (d) Any person who violates this Section with regard to any | 26 | | other
amount of a controlled or counterfeit substance |
| | | HB2534 Enrolled | - 51 - | LRB100 08419 RLC 18533 b |
|
| 1 | | containing dihydrocodeinone or dihydrocodeine or classified in
| 2 | | Schedules I or II, or an analog thereof, which is (i) a | 3 | | narcotic
drug, (ii) lysergic acid diethylamide (LSD) or an | 4 | | analog thereof,
(iii) any
substance containing amphetamine or | 5 | | fentanyl or any salt or optical
isomer of amphetamine or | 6 | | fentanyl, or an analog thereof, or (iv) any
substance | 7 | | containing N-Benzylpiperazine (BZP) or any salt or optical
| 8 | | isomer of N-Benzylpiperazine (BZP), or an analog thereof, is | 9 | | guilty
of a Class 2 felony. The fine for violation of this | 10 | | subsection (d) shall
not be more than $200,000.
| 11 | | (d-5) (Blank).
| 12 | | (e) Any person who violates this Section with regard to any | 13 | | other
amount of a controlled substance other than | 14 | | methamphetamine or counterfeit substance classified in
| 15 | | Schedule I or II, or an analog thereof, which substance is not
| 16 | | included under subsection (d) of this Section, is
guilty of a | 17 | | Class 3 felony. The fine for violation of this subsection (e)
| 18 | | shall not be more than $150,000.
| 19 | | (f) Any person who violates this Section with regard to any | 20 | | other
amount of a controlled or counterfeit substance | 21 | | classified in
Schedule III is guilty of a Class 3 felony. The | 22 | | fine for violation of
this subsection (f) shall not be more | 23 | | than $125,000.
| 24 | | (g) Any person who violates this Section with regard to any | 25 | | other
amount of a controlled or counterfeit substance | 26 | | classified
in Schedule IV is guilty of a Class 3 felony. The |
| | | HB2534 Enrolled | - 52 - | LRB100 08419 RLC 18533 b |
|
| 1 | | fine for violation of
this subsection (g) shall not be more | 2 | | than $100,000.
| 3 | | (h) Any person who violates this Section with regard to any | 4 | | other
amount of a controlled or counterfeit substance | 5 | | classified in
Schedule V is guilty of a Class 3 felony. The | 6 | | fine for violation of this
subsection (h) shall not be more | 7 | | than $75,000.
| 8 | | (i) This Section does not apply to the manufacture, | 9 | | possession or
distribution of a substance in conformance with | 10 | | the provisions of an approved
new drug application or an | 11 | | exemption for investigational use within the
meaning of Section | 12 | | 505 of the Federal Food, Drug and Cosmetic Act.
| 13 | | (j) (Blank).
| 14 | | (Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17 .)
| 15 | | (720 ILCS 570/402) (from Ch. 56 1/2, par. 1402)
| 16 | | Sec. 402. Except as otherwise authorized by this Act, it is | 17 | | unlawful for
any person knowingly to possess a controlled or | 18 | | counterfeit substance or controlled substance analog.
A | 19 | | violation of this Act with respect to each of the controlled | 20 | | substances
listed herein constitutes a single and separate | 21 | | violation of this Act. For purposes of this Section, | 22 | | "controlled substance analog" or "analog"
means a substance, | 23 | | other than a controlled substance, which is not approved by the | 24 | | United States Food and Drug Administration or, if approved, is | 25 | | not dispensed or possessed in accordance with State or federal |
| | | HB2534 Enrolled | - 53 - | LRB100 08419 RLC 18533 b |
|
| 1 | | law, and that has a chemical structure substantially similar to | 2 | | that of a controlled
substance in Schedule I or II, or that was | 3 | | specifically designed to produce
an effect substantially | 4 | | similar to that of a controlled substance in Schedule
I or II. | 5 | | Examples of chemical classes in which controlled substance | 6 | | analogs
are found include, but are not limited to, the | 7 | | following: phenethylamines,
N-substituted piperidines, | 8 | | morphinans, ecgonines, quinazolinones, substituted
indoles, | 9 | | and arylcycloalkylamines. For purposes of this Act, a | 10 | | controlled
substance analog shall be treated in the same manner | 11 | | as the controlled
substance to which it is substantially | 12 | | similar.
| 13 | | (a) Any person who violates this Section with respect to | 14 | | the following
controlled or counterfeit substances and | 15 | | amounts, notwithstanding any of the
provisions of subsections | 16 | | (c) and (d) to the
contrary, is guilty of a Class 1 felony and | 17 | | shall, if sentenced to a term
of imprisonment, be sentenced as | 18 | | provided in this subsection (a) and fined
as provided in | 19 | | subsection (b):
| 20 | | (1) (A) not less than 4 years and not more than 15 | 21 | | years with respect
to 15 grams or more but less than | 22 | | 100 grams of a substance containing heroin;
| 23 | | (B) not less than 6 years and not more than 30 | 24 | | years with respect to 100
grams or more but less than | 25 | | 400 grams of a substance containing heroin;
| 26 | | (C) not less than 8 years and not more than 40 |
| | | HB2534 Enrolled | - 54 - | LRB100 08419 RLC 18533 b |
|
| 1 | | years with respect to 400
grams or more but less than | 2 | | 900 grams of any substance containing heroin;
| 3 | | (D) not less than 10 years and not more than 50 | 4 | | years with respect to
900 grams or more of any | 5 | | substance containing heroin;
| 6 | | (2) (A) not less than 4 years and not more than 15 | 7 | | years with respect
to 15 grams or more but less than | 8 | | 100 grams of any substance containing
cocaine;
| 9 | | (B) not less than 6 years and not more than 30 | 10 | | years with respect to 100
grams or more but less than | 11 | | 400 grams of any substance containing cocaine;
| 12 | | (C) not less than 8 years and not more than 40 | 13 | | years with respect to 400
grams or more but less than | 14 | | 900 grams of any substance containing cocaine;
| 15 | | (D) not less than 10 years and not more than 50 | 16 | | years with respect to
900 grams or more of any | 17 | | substance containing cocaine;
| 18 | | (3) (A) not less than 4 years and not more than 15 | 19 | | years with respect
to 15 grams or more but less than | 20 | | 100 grams of any substance containing
morphine;
| 21 | | (B) not less than 6 years and not more than 30 | 22 | | years with respect to 100
grams or more but less than | 23 | | 400 grams of any substance containing morphine;
| 24 | | (C) not less than 6 years and not more than 40 | 25 | | years with respect to 400
grams or more but less than | 26 | | 900 grams of any substance containing morphine;
|
| | | HB2534 Enrolled | - 55 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (D) not less than 10 years and not more than 50 | 2 | | years with respect to
900 grams or more of any | 3 | | substance containing morphine;
| 4 | | (4) 200 grams or more of any substance containing | 5 | | peyote;
| 6 | | (5) 200 grams or more of any substance containing a | 7 | | derivative of
barbituric acid or any of the salts of a | 8 | | derivative of barbituric acid;
| 9 | | (6) 200 grams or more of any substance containing | 10 | | amphetamine or any salt
of an optical isomer of | 11 | | amphetamine;
| 12 | | (6.5) (blank);
| 13 | | (7) (A) not less than 4 years and not more than 15 | 14 | | years with respect
to: (i) 15 grams or more but less | 15 | | than 100 grams of any substance containing
lysergic | 16 | | acid diethylamide (LSD), or an analog thereof, or (ii) | 17 | | 15 or
more objects or 15 or more segregated parts of an | 18 | | object or objects but
less than 200 objects or 200 | 19 | | segregated parts of an object or objects
containing in | 20 | | them or having upon them any amount of any substance
| 21 | | containing lysergic acid diethylamide (LSD), or an | 22 | | analog thereof;
| 23 | | (B) not less than 6 years and not more than 30 | 24 | | years with respect
to: (i) 100 grams or more but less | 25 | | than 400 grams of any substance
containing lysergic | 26 | | acid diethylamide (LSD), or an analog thereof, or (ii)
|
| | | HB2534 Enrolled | - 56 - | LRB100 08419 RLC 18533 b |
|
| 1 | | 200 or more objects or 200 or more segregated parts of | 2 | | an object or objects
but less than 600 objects or less | 3 | | than 600 segregated parts of an object or
objects | 4 | | containing in them or having upon them any amount of | 5 | | any substance
containing lysergic acid diethylamide | 6 | | (LSD), or an analog thereof;
| 7 | | (C) not less than 8 years and not more than 40 | 8 | | years with respect
to: (i) 400 grams or more but less | 9 | | than 900 grams of any substance
containing lysergic | 10 | | acid diethylamide (LSD), or an analog thereof, or (ii)
| 11 | | 600 or more objects or 600 or more segregated parts of | 12 | | an object or objects
but less than 1500 objects or 1500 | 13 | | segregated parts of an object or objects
containing in | 14 | | them or having upon them any amount of any substance
| 15 | | containing lysergic acid diethylamide (LSD), or an | 16 | | analog thereof;
| 17 | | (D) not less than 10 years and not more than 50 | 18 | | years with respect
to: (i) 900 grams or more of any | 19 | | substance containing lysergic acid
diethylamide (LSD), | 20 | | or an analog thereof, or (ii) 1500 or more objects or
| 21 | | 1500 or more segregated parts of an object or objects | 22 | | containing in them or
having upon them any amount of a | 23 | | substance containing lysergic acid
diethylamide (LSD), | 24 | | or an analog thereof;
| 25 | | (7.5) (A) not less than 4 years and not more than 15 | 26 | | years with respect
to: (i) 15
grams or more but
less |
| | | HB2534 Enrolled | - 57 - | LRB100 08419 RLC 18533 b |
|
| 1 | | than 100 grams of any substance listed in paragraph | 2 | | (1), (2), (2.1), (2.2), (3),
(14.1), (19),
(20), | 3 | | (20.1), (21), (25), or (26) of subsection (d) of | 4 | | Section 204, or an
analog or derivative
thereof, or | 5 | | (ii) 15 or more pills, tablets, caplets, capsules, or | 6 | | objects but
less than 200 pills,
tablets, caplets, | 7 | | capsules, or objects containing in them or having upon | 8 | | them
any amount of any
substance listed in paragraph | 9 | | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), | 10 | | (20.1),
(21), (25), or (26) of
subsection (d) of | 11 | | Section 204, or an analog or derivative thereof;
| 12 | | (B) not less than 6 years and not more than 30 | 13 | | years with respect to: (i)
100
grams or more but
less | 14 | | than 400 grams of any substance listed in paragraph | 15 | | (1), (2), (2.1), (2.2), (3),
(14.1), (19), (20),
| 16 | | (20.1), (21), (25), or (26) of subsection (d) of | 17 | | Section 204, or an analog or
derivative thereof, or
| 18 | | (ii) 200 or more pills, tablets, caplets, capsules, or | 19 | | objects but less than
600
pills, tablets,
caplets, | 20 | | capsules, or objects containing in them or having upon | 21 | | them any amount
of any
substance
listed in paragraph | 22 | | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), | 23 | | (20.1), (21),
(25), or (26) of subsection
(d) of | 24 | | Section 204, or an analog or derivative thereof;
| 25 | | (C) not less than 8 years and not more than 40 | 26 | | years with respect to: (i)
400
grams or more but
less |
| | | HB2534 Enrolled | - 58 - | LRB100 08419 RLC 18533 b |
|
| 1 | | than 900 grams of any substance listed in paragraph | 2 | | (1), (2), (2.1), (2.2), (3),
(14.1), (19), (20),
| 3 | | (20.1), (21), (25), or (26) of subsection (d) of | 4 | | Section 204, or an analog or
derivative thereof,
or | 5 | | (ii) 600 or more pills, tablets, caplets, capsules, or | 6 | | objects but less than
1,500 pills, tablets,
caplets, | 7 | | capsules, or objects containing in them or having upon | 8 | | them any amount
of any
substance listed in paragraph | 9 | | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), | 10 | | (20.1),
(21), (25), or (26) of
subsection (d) of | 11 | | Section 204, or an analog or derivative thereof;
| 12 | | (D) not less than 10 years and not more than 50 | 13 | | years with respect to:
(i)
900 grams or more of
any | 14 | | substance listed in paragraph (1), (2), (2.1), (2.2), | 15 | | (3), (14.1), (19), (20),
(20.1), (21), (25), or (26)
of | 16 | | subsection (d) of Section 204, or an analog or | 17 | | derivative thereof, or (ii)
1,500 or more pills,
| 18 | | tablets, caplets, capsules, or objects containing in | 19 | | them or having upon them
any amount of a
substance | 20 | | listed in paragraph (1), (2), (2.1), (2.2), (3), | 21 | | (14.1), (19), (20), (20.1),
(21), (25), or (26) of
| 22 | | subsection (d) of Section 204, or an analog or | 23 | | derivative thereof;
| 24 | | (8) 30 grams or more of any substance containing | 25 | | pentazocine or any of
the salts, isomers and salts of | 26 | | isomers of pentazocine, or an analog thereof;
|
| | | HB2534 Enrolled | - 59 - | LRB100 08419 RLC 18533 b |
|
| 1 | | (9) 30 grams or more of any substance containing | 2 | | methaqualone or any
of the salts, isomers and salts of | 3 | | isomers of methaqualone;
| 4 | | (10) 30 grams or more of any substance containing | 5 | | phencyclidine or any
of the salts, isomers and salts of | 6 | | isomers of phencyclidine (PCP);
| 7 | | (10.5) 30 grams or more of any substance containing | 8 | | ketamine or any of
the salts, isomers and salts of isomers | 9 | | of ketamine;
| 10 | | (11) 200 grams or more of any substance containing any | 11 | | substance
classified as a narcotic drug in Schedules I or | 12 | | II, or an analog thereof, which is not otherwise
included | 13 | | in this subsection.
| 14 | | (b) Any person sentenced with respect to violations of | 15 | | paragraph (1),
(2), (3), (7), or (7.5) of subsection (a) | 16 | | involving 100
grams or more of the
controlled substance named | 17 | | therein, may in addition to the penalties
provided therein, be | 18 | | fined an amount not to exceed $200,000 or the full
street value | 19 | | of the controlled or counterfeit substances, whichever is
| 20 | | greater. The term "street value" shall have the meaning
| 21 | | ascribed in Section 110-5 of the Code of Criminal Procedure of | 22 | | 1963. Any
person sentenced with respect to any other provision | 23 | | of subsection (a), may
in addition to the penalties provided | 24 | | therein, be fined an amount not to
exceed $200,000.
| 25 | | (c) Any person who violates this Section with regard to an | 26 | | amount
of a controlled substance other than methamphetamine or |
| | | HB2534 Enrolled | - 60 - | LRB100 08419 RLC 18533 b |
|
| 1 | | counterfeit substance not set forth in
subsection (a) or (d) is | 2 | | guilty of a Class 4 felony. The fine for a
violation punishable | 3 | | under this subsection (c) shall not be more
than $25,000.
| 4 | | (d) Any person who violates this Section with regard to any | 5 | | amount of
anabolic steroid is guilty of a Class C misdemeanor
| 6 | | for the first offense and a Class B misdemeanor for a | 7 | | subsequent offense
committed within 2 years of a prior | 8 | | conviction.
| 9 | | (Source: P.A. 99-371, eff. 1-1-16 .)
|
|